Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.67 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.67 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.64 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.64 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7912731 | 0.91 | P2RY6 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL23344550 | 0.90 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL28889687 | 0.90 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL31229960 | 0.90 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL336760 | 0.89 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL21678787 | 0.88 | P2RY6 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL25174534 | 0.88 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL4741075 | 0.86 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL4950157 | 0.86 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL21742397 | 0.86 | SLC28A1 (0.65) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076620-A | Process for producing 2' -modified pyrimidine nucleoside | 日产化学株式会社 | 2024-05-24 | — | — | CN | claimed |
| CN-115181147-B | Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid | 南开大学 | 2024-04-02 | — | — | CN | claimed |
| CN-109071588-A | Uridine phosphamide prodrug, preparation method and application thereof in medicine | 江苏天士力帝益药业有限公司 | 2018-12-21 | — | — | CN | claimed |
| US-9920319-B2 | 2′/3′/5′-(R/S)-serinyl functionalized oligonucleotides | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-03-20 | — | — | US | claimed |
| US-20170044527-A1 | Novel 2'/3'/5'-(R/S)-Serinyl Functionalized Oligonucleotides | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-02-16 | — | — | US | claimed |
| WO-2014178082-A1 | NOVEL 2'/3'/5'-(R/S)-SERINYL FUNCTIONALIZED OLIGONUCLEOTIDES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-11-06 | — | — | WO | claimed |
| CN-104011209-A | Inhibition Of Viral Gene Expression | UNIV WITWATERSRAND JHB | 2014-08-27 | — | — | CN | claimed |
| US-20120178710-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-07-12 | — | — | US | claimed |
| EP-2448954-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | Rutgers, The State University of New Jersey (US) | 2012-05-09 | — | — | EP | claimed |
| WO-2011003025-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-01-06 | — | — | WO | claimed |
| WO-2008080060-A2 | 4-SE-THYMIDINE DERIVATIVES, 4-SE-URIDINE DERIVATIVES, DI (2-CYANOETHYL) DISELENIDE, AND METHODS | GEORGIA STATE UNIVERSITY (US) | 2008-07-03 | — | — | WO | claimed |
| US-12629426-B2 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | DYNE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12624120-B2 | Anti-transferrin receptor (TfR) antibody and uses thereof | DYNE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260109989-A1 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS AND IDENTIFICATION OF COVALENT APTAMERS | UNIV HAWAII (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4694931-A1 | EXTRAHEPATIC DELIVERY OF DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-1995006659-A1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| EP-0571087-A1 | Cleavable phosphoramidites | ROHM AND HAAS COMPANY (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624120-B2 | Anti-transferrin receptor (TfR) antibody and uses thereof | FTH1, TFRC, VSIG8 | SLC28A1 2554/4885SLC28A2 2540/4885SLC29A1 1224/4885 |
| US-20260109989-A1 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS AND IDENTIFICATION OF COVALENT APTAMERS | DNMT3A, PCNA, DNMT3L | SLC28A1 329/4885SLC28A2 446/4885SLC29A1 29/4885 |
| US-20170044527-A1 | Novel 2'/3'/5'-(R/S)-Serinyl Functionalized Oligonucleotides | RNGTT, NSUN2, ADAR | SLC28A1 1046/4885SLC28A2 657/4885SLC29A1 448/4885 |
| US-20120178710-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | TYMP, DTYMK, MTAP | SLC28A1 359/4885SLC28A2 349/4885SLC29A1 244/4885 |
| US-12629426-B2 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | MYOF, MUSK, UPF1 | SLC28A1 2152/4885SLC28A2 1592/4885SLC29A1 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.